0000899243-22-031355.txt : 20220916 0000899243-22-031355.hdr.sgml : 20220916 20220916180107 ACCESSION NUMBER: 0000899243-22-031355 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220916 FILED AS OF DATE: 20220916 DATE AS OF CHANGE: 20220916 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sokol Gerald H CENTRAL INDEX KEY: 0001711894 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38169 FILM NUMBER: 221248988 MAIL ADDRESS: STREET 1: 44 WALL STREET STREET 2: 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TYME TECHNOLOGIES, INC. CENTRAL INDEX KEY: 0001537917 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453864597 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 1 PLUCKEMIN WAY - SUITE 103 CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: 212-461-2315 MAIL ADDRESS: STREET 1: 1 PLUCKEMIN WAY - SUITE 103 CITY: BEDMINSTER STATE: NJ ZIP: 07921 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL GROUP ENTERPRISES CORP. DATE OF NAME CHANGE: 20111221 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-09-16 1 0001537917 TYME TECHNOLOGIES, INC. TYME 0001711894 Sokol Gerald H C/O TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY - SUITE 103 BEDMINSTER NJ 07921 1 0 0 0 Common Stock 2022-09-16 4 D 0 5865 D 0 D Director Stock Option - Option to buy 8.75 2022-09-16 4 D 0 25000 D 2026-05-09 Common Stock 25000 0 D Director Stock Option - Option to buy 2.90 2022-09-16 4 D 0 75000 D 2028-05-24 Common Stock 75000 0 D Director Stock Option - Option to buy 2.33 2022-09-16 4 D 0 50000 D 2028-08-26 Common Stock 50000 0 D Director Stock Option - Option to buy 1.18 2022-09-16 4 D 0 50000 D 2029-08-22 Common Stock 50000 0 D Director Stock Option - Option to buy 1.22 2022-09-16 4 D 0 65000 D 2030-08-19 Common Stock 65000 0 D Director Stock Option - Option to buy 1.10 2022-09-16 4 D 0 88000 D 2031-08-23 Common Stock 88000 0 D Director Stock Option - Option to buy 0.31 2022-09-16 4 D 0 88000 D 2032-08-23 Common Stock 88000 0 D Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 257 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 1,094 shares of Syros common stock for $199.68 per share, after giving effect to the Reverse Split. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,286 shares of Syros common stock for $66.18 per share, after giving effect to the Reverse Split. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $53.17 per share, after giving effect to the Reverse Split. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split. By: /s/ Richard Cunningham as attorney-in-fact for Gerald H. Sokol 2022-09-16